Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection, Ozempic, has won FDA approval as a therapy for adults with Type II diabetes, the insulin-maker reported today.
The injection, given in a pre-filled pen, is a GLP-1 analogue – a drug that trigger the production of insulin, while lessening appetite and food intake.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk’s once-weekly Type II diabetes injection wins FDA nod appeared first on MassDevice.